Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0ZF9J
|
|||
| Drug Name |
HuCART-meso cells
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | Lymphatic disease [ICD-11: BD9Z] | Phase 1 | [1] | |
| Pancreatic cancer [ICD-11: 2C10] | Phase 1 | [1] | ||
| Pediatric cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-C96; ICD-9: 140-229] | Phase 1 | [1] | ||
| Company |
University of Pennsylvania
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Mesothelin (MSLN) | Target Info | CAR-T-Cell-Therapy | [1] |
| NetPath Pathway | TCR Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03323944) CAR T Cell Immunotherapy for Pancreatic Cancer | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.